Cyrano Therapeutics和 Resyca宣布达成独家许可协议，将软雾鼻喷技术用于治疗化学感官功能障碍-动脉网

Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction

CISION 等信源发布 2025-03-18 20:33



可切换为仅中文







Soft Mist Nasal Spray Technology Designed to Enhance Drug Deposition in the Olfactory Region, Increasing the Potential for CYR-064's Therapeutic Efficacy

软雾鼻喷技术旨在增强药物在嗅觉区域的沉积，提高CYR-064的治疗效果潜力。

DELRAY BEACH, Fla

德雷海滩，佛罗里达州

and ENSCHEDE,

和恩斯赫德，

Netherlands

荷兰

，

March 18, 2025

2025年3月18日

/PRNewswire/ -- Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, and Resyca, a leading innovator in soft mist inhaler and soft nasal spray technologies, today announced they have entered into an exclusive licensing agreement for Resyca's proprietary soft mist nasal spray technology for the treatment of chemosensory disorders, including post-viral smell loss (hyposmia)..

/PRNewswire/ -- 致力于开发嗅觉丧失治疗方法的临床阶段再生医学公司Cyrano Therapeutics，与软雾吸入器和软鼻喷雾技术领域的领先创新者Resyca今天宣布，双方已就Resyca专有的软雾鼻喷技术达成独家许可协议，用于治疗化学感官障碍，包括病毒感染后嗅觉丧失（嗅觉减退）。

This agreement marks a major milestone in advancing an innovative treatment to address this critical unmet medical need. Cyrano Therapeutics' lead therapy, CYR-064, has progressed its Phase 2 FLAVOR clinical study utilizing Resyca's soft mist nasal spray technology, with top-line data expected in the second half of 2025..

该协议标志着推进一种创新疗法以解决这一关键未满足医疗需求的重大里程碑。Cyrano Therapeutics 的主导疗法 CYR-064 已利用 Resyca 的软雾鼻喷技术推进其第二阶段 FLAVOR 临床研究，预计将在 2025 年下半年获得初步数据。

Resyca's proprietary soft mist nasal spray technology is designed to optimize drug deposition in the nasal cavity and the olfactory region. Specific to CYR-064, the precisely controlled droplet size and low spray velocity have the potential to improve drug distribution to the target olfactory region, thereby increasing the opportunity for therapeutic efficacy.

Resyca专有的软雾鼻喷技术旨在优化药物在鼻腔和嗅觉区域的沉积。对于CYR-064而言，精确控制的液滴大小和较低的喷射速度有可能改善药物向目标嗅觉区域的分布，从而增加治疗效果的机会。

Integrated into Ursatec's spray pump technology, Resyca's soft mist technology offers a patient-friendly design that supports safe and effective administration, making it particularly well-suited for treating persistent smell loss..

整合到 Ursatec 的喷雾泵技术中，Resyca 的软雾技术提供了一种对患者友好的设计，支持安全有效的给药，特别适合用于治疗持续的嗅觉丧失。

'This agreement with Resyca enables us to enhance the efficacy of our treatment for patients experiencing chemosensory dysfunction by delivering our proprietary formulation through their advanced soft mist technology,' said

“与Resyca的这项协议使我们能够通过他们先进的软雾技术来提供我们的专利配方，从而提高我们对经历化学感官功能障碍患者的治疗效果，”

Rick Geoffrion

里克·杰夫里翁

, CEO of Cyrano Therapeutics. 'Resyca's soft mist technology plays a critical role in optimizing the deposition and delivery of CYR-064 in the olfactory region to maximize its therapeutic potential. This advanced delivery system has been integral to our Phase 2 FLAVOR trial, which is currently wrapping up enrollment.'.

Cyrano Therapeutics首席执行官表示：“Resyca的软雾技术在优化CYR-064在嗅觉区域的沉积和递送方面发挥着关键作用，以最大限度地发挥其治疗潜力。这一先进的递送系统对我们目前正在完成入组的2期FLAVOR试验至关重要。”

Remko Beimers

雷姆科·贝默斯

, CEO of Resyca, added, 'Our patented nasal soft mist technology enables advanced drug delivery for both biologics and small molecules. Partnering with Cyrano Therapeutics aligns with our mission to drive innovation in drug delivery solutions. We believe this collaboration will help patients regain their sense of smell, achieve better treatment outcomes, and create a barrier to entry for any future competitors.'.

Resyca首席执行官补充道：“我们获得专利的鼻腔软雾技术能够为生物制剂和小分子提供先进的药物递送方式。与Cyrano Therapeutics合作符合我们推动药物递送解决方案创新的使命。我们相信，此次合作将帮助患者恢复嗅觉、取得更好的治疗效果，并为未来任何竞争对手设置进入壁垒。”

As the development of Cyrano Therapeutics' product CYR-064 progresses toward commercialization, Cyrano Therapeutics and Resyca are committed to bringing this innovative treatment to patients with chemosensory disorders. This partnership underscores their shared dedication to scientific innovation, patient-focused drug delivery, and advancing therapeutic solutions for smell loss..

随着Cyrano Therapeutics的产品CYR-064的开发朝着商业化方向进展，Cyrano Therapeutics和Resyca致力于将这种创新疗法带给化学感官障碍患者。这一合作突显了他们对科学创新、以患者为中心的药物递送以及推进嗅觉丧失治疗方案的共同承诺。

Hyposmia, including post-viral hyposmia, is an increasingly prevalent and serious chronic sensory condition for which there is no approved drug therapy and limited treatment options. Hyposmia causes significant impairment in quality of life for many sufferers. Moreover, in older individuals, hyposmia is associated with an increased risk of cognitive impairment and mortality.

嗅觉减退，包括病毒感染后嗅觉减退，是一种日益普遍且严重的慢性感官疾病，目前尚无获批的药物治疗，且治疗选择有限。嗅觉减退对许多患者的生活质量造成了显著影响。此外，在老年人中，嗅觉减退与认知障碍和死亡风险增加相关。

There is currently no FDA-approved therapy indicated for the treatment of smell loss..

目前尚无FDA批准的用于治疗嗅觉丧失的疗法。

About Cyrano Therapeutics

关于Cyrano Therapeutics

Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop therapies for people struggling with the loss of smell and taste.

Cyrano Therapeutics 是一家私人控股的、处于临床阶段的再生医学公司，受到风险投资支持。自成立以来，我们一直致力于为那些失去嗅觉和味觉的人们开发疗法。

To learn more, please visit

要了解更多信息，请访问

cyranotherapeutics.com

西冉治疗学公司网站

。

About Resyca

关于Resyca

Resyca® was founded in 2020 and is a joint venture between Bespak and Medspray. Resyca® specialises in the development and manufacturing of compact, user-friendly soft mist inhalation and soft nasal spray devices, incorporating the proprietary Medspray micro-nozzle technology. These devices are tailored for pulmonary and nasal applications, utilising standard pre-filled syringes / primary packaging and filling lines.

Resyca® 成立于2020年，是Bespak和Medspray的合资企业。Resyca® 专注于开发和制造紧凑、用户友好的软雾吸入器和软鼻喷装置，采用专有的Medspray微喷嘴技术。这些装置专为肺部和鼻腔应用设计，使用标准预填充注射器/初级包装和灌装生产线。

As the soft mist development centre within Bespak, Resyca offers comprehensive services spanning from early-stage development through to commercial production, inclusive of filling, labelling, and packaging..

作为 Bespak 内的软雾开发中心，Resyca 提供从早期开发到商业生产的全面服务，包括填充、贴标和包装。

To learn more, please visit

要了解更多信息，请访问

www.resyca.com

Media Contact:

媒体联系人：

Tiberend Strategic Advisors, Inc.

蒂贝伦德战略顾问公司

Eric Reiss

埃里克·赖斯

ereiss@tiberend.com

SOURCE Cyrano Therapeutics